A

nd then there were … oh, forget it: We’ve given up trying to count the number of CRISPR companies, but we can tell you that one more came out of stealth mode on Thursday. After a year spent wooing investors, hiring, and refining its plans, Mammoth Biosciences, co-founded by CRISPR developer Jennifer Doudna, is announcing its entry into the ever-more-crowded fields of diagnostics and genome-editing, and hoping to find a sweet spot at their intersection.

“Mammoth Biosciences is all about building a CRISPR-based platform for disease detection,” said CEO Trevor Martin, who got a Ph.D. in genetics and statistics from Stanford in 2016.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy